Tight blood sugar control in hospital: help or harm?

NCT ID NCT03510078

Completed Disease control Sponsor: Rabin Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether keeping blood sugar very low (under 130 mg/dL) is better than standard control (130-180 mg/dL) for non-critically ill patients with diabetes in the hospital. Researchers tracked 600 patients for complications like death, severe low blood sugar, infections, and heart issues within 30 days. The goal is to find the safest glucose target for hospitalized patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Insulin
What this could lead to: If it works, this could help doctors choose the best blood sugar target for hospitalized patients to reduce complications like infections or heart events.
What could go wrong: This trial is completed but results may not apply to all patients. Intensive control could increase the risk of dangerously low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS NON-CRITICALLY ILL PATIENTS

Contacts and locations

Locations

Rabin Medical Center

Petah Tikva, Israel, Israel
Rambam Medical Center

Haifa, Israel
Shamir Medical Center

Ẕerifin, Israel
Soroka University Medical Center

Beersheba, Israel
Unit of Geriatric Medicine University of Modena and Reggio Emilia, University Hospital of Baggiovara

Modena, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.